It is often said that “disease knows no borders,” but is the same true for clinical development?
Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match...
APAC As A Clinical Trials Powerhouse
Half Of Global New Activity in 2021
In the last 10 years, the Asia Pacific region has become a hotspot for clinical trials, contributing almost 50% of new clinical trial activity globally in 2021, a new infographic analysis by Citeline's Trialtrove shows.
More from Focus On Asia
• By
Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.
• By
Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.
• By
Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.
• By
Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.